1. Search Result
Search Result
Results for "

Blood-brain barrier

" in MCE Product Catalog:

925

抑制剂 & 激动剂

6

化合物筛选库

14

荧光染料

12

生化试剂

47

多肽产品

3

抗体抑制剂

98

天然产物

73

同位素标记物

2

点击化学

6

寡核苷酸

没找到您心仪的产品?我们拥有更多针对信号通路的抑制剂、激动剂、调节剂

您还可以尝试以下方式,我们的专业人员为您服务

Cat. No. Product Name
  • HY-L919
    28000 compounds

    随着人口老龄化和竞争压力的增加,中枢神经系统退行性疾病已变成现代社会严重的医学问题,例如帕金森病、阿尔兹海默症、脑肿瘤和多发性硬化。然而中枢药物研发成功率却很低,这主要与血脑屏障(blood-brain barrier, BBB)有关。 血脑屏障(BBB)是包围中枢神经系统(CNS)微血管系统的半透性屏障结构。在毛细血管中,紧密排列的内皮细胞排列在血管内部,形成广泛的紧密连接。该屏障与一系列受体、转运蛋白、外排泵和其他细胞成分一起,控制着血管内分子进入和排出大脑。完整的血脑屏障不仅能够阻止大多数血液中的物质流入大脑,还能将大分子药物的通过率限制在近乎为零,同时屏蔽超过 98% 的小分子药物,从而为中枢神经系统营造稳定的内环境。 与非中枢神经系统药物相比,氢键、脂溶性和分子大小等理化性质较大影响化合物的血脑屏障通透能力。使用人工智能算法预测血脑屏障通透性,当预测值大于0.75时,意味着该化合物具备良好的透过血脑屏障的潜力,为中枢神经系统药物发现提供了良好的起点。

  • HY-L0124V
    13,082 compounds
    The basic requirements for the compounds that are supposed to penetrate the blood-brain barrier are somewhat different from those for the majority of drug discovery projects. Alongside the known problem with delivery of the large and non-polar compounds and their penetrability through the cell membrane, the other issue arises as well: small and polar compounds are not able to pass the Blood-Brain Barrier. Chemspace CNS-focused library comprises quite small, non-polar compounds that are also free from PAINS/toxic fragments and aggregators.
  • HY-L028
    979 compounds

    血脑屏障是一种复杂的大脑微血管网络。它保护大脑免受外部血流环境的影响,并为大脑提供正常功能所需的营养。然而,血脑屏障也是中枢神经系统疾病或脑肿瘤治疗药物运送的主要障碍,因为由于物理屏障 (紧密连接) 的存在,血脑屏障在全身毛细血管中通透性最低。因此,开发能够透过血脑屏障的药物用于治疗脑部疾病,如阿尔茨海默病 (AD)、帕金森病 (PD) 和癫痫等是至关重要的。

    MCE 收录了 979 个具有明确报道可以透过血脑屏障的小分子化合物,是开发脑部疾病药物如脑瘤、精神障碍和神经退行性疾病等有效的工具。

  • HY-L0065V
    47,360 compounds
    A unique collection of 47,360 novel small molecules with high CNS MPO (Central Nervous System Multiparameter Optimization) scores. The CNS-active molecules which are able to penetrate blood-brain barrier (BBB) were low polar surface area, low degree of possible hydrogen bond formation and low ClogP values.
  • HY-L0123V
    30,300 compounds

    The incidence and significance of central nervous system diseases are increasing at an alarming rate all over the world. Although substantial research efforts have been applied to develop new CNS-active drugs, only a few CNS disorders are addressed satisfactorily, while the remaining ones pose significant clinical challenges. Blood-brain barrier (BBB) permeability is one of the most important limiting factors in the design and development of novel CNS-targeted pharmaceuticals for the treatment of neurological disorders.

    Carefully selected from the HTS Compound Collection to meet the parameters optimized for high BBB-permeability, our CNS Focused Screening Library comprising over 30,300 structurally-diverse and potentially CNS-active screening compounds. This original Screening Compound Library is aimed at supporting CNS drug design projects and HTS efforts in search for novel neurotherapeutics.

  • HY-L920
    25000 compounds
    随着人口老龄化和竞争压力的增加,中枢神经系统退行性疾病已变成现代社会严重的医学问题,例如帕金森病、阿尔兹海默症、脑肿瘤和多发性硬化。 CNS MPO 评分是药物化学界比较公认的算法,该方法是Pfizer基于上市的CNS药物和其开发过的CNS药物总结出的CNS MPO规则,涉及六种基本理化性质(ClogP、ClogD、MW、TPSA、HBD和pKa),以概率的方式前瞻性地调整CNS的药物属性,包括高渗透性、低P-gp外排倾向、低代谢清除率和高安全性,提高了CNS药物进入临床的成功率。 CNS MPO化合物库是基于CNS MPO算法计算,筛选CNS MPO打分大于5的化合物集合,专门针对中枢神经系统(CNS)药物发现而设计。

Your information is safe with us. * Required Fields.

* 客户姓名:

 

* 公司或机构名称:

* Email:

 

* 联系电话:

* 产品名称:

 

* 需求量:

   目录号:

 

   CAS号:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
目录号:
需求量: